Moderna’s First mRNA Flu Shot Just Won FDA Approval. Now Researchers See Potential for HIV and Malaria

The FDA approved mFlusiva, a new flu vaccine from Moderna for adults aged 50 and older. This is the first influenza shot utilizing mRNA technology, similar to COVID-19 vaccines. While other brands are already in pharmacies for the fall season, Moderna expects availability soon at select retailers. Researchers believe this approval strengthens the case for using mRNA against cancer, HIV, and malaria, providing a new tool to reduce the thousands of annual influenza deaths in the U.S.